Scheeren HW - Search Results

1

Plasmin-activated doxorubicin prodrugs containing a spacer reduce tumor growth and angiogenesis without systemic toxicity.

Devy L, de Groot FM, Blacher S, Hajitou A, Beusker PH, Scheeren HW, Foidart JM, Noël A. Devy L, et al. Among authors: scheeren hw. FASEB J. 2004 Mar;18(3):565-7. doi: 10.1096/fj.03-0462fje. Epub 2004 Jan 20. FASEB J. 2004. PMID: 14734647

2

Novel 20-carbonate linked prodrugs of camptothecin and 9-aminocamptothecin designed for activation by tumour-associated plasmin.

de Groot FM, Busscher GF, Aben RW, Scheeren HW. de Groot FM, et al. Among authors: scheeren hw. Bioorg Med Chem Lett. 2002 Sep 2;12(17):2371-6. doi: 10.1016/s0960-894x(02)00388-8. Bioorg Med Chem Lett. 2002. PMID: 12161136

3

Synthesis and biological evaluation of 2'-carbamate-linked and 2'-carbonate-linked prodrugs of paclitaxel: selective activation by the tumor-associated protease plasmin.

de Groot FM, van Berkom LW, Scheeren HW. de Groot FM, et al. Among authors: scheeren hw. J Med Chem. 2000 Aug 10;43(16):3093-102. doi: 10.1021/jm0009078. J Med Chem. 2000. PMID: 10956217

4

Anticancer prodrugs for application in monotherapy: targeting hypoxia, tumor-associated enzymes, and receptors.

de Groot FM, Damen EW, Scheeren HW. de Groot FM, et al. Among authors: scheeren hw. Curr Med Chem. 2001 Jul;8(9):1093-122. doi: 10.2174/0929867013372634. Curr Med Chem. 2001. PMID: 11472243 Review.

5

Design, synthesis, and biological evaluation of a dual tumor-specific motive containing integrin-targeted plasmin-cleavable doxorubicin prodrug.

de Groot FM, Broxterman HJ, Adams HP, van Vliet A, Tesser GI, Elderkamp YW, Schraa AJ, Kok RJ, Molema G, Pinedo HM, Scheeren HW. de Groot FM, et al. Among authors: scheeren hw. Mol Cancer Ther. 2002 Sep;1(11):901-11. Mol Cancer Ther. 2002. PMID: 12481411

6

Synthesis and biological evaluation of novel prodrugs of anthracyclines for selective activation by the tumor-associated protease plasmin.

de Groot FM, de Bart AC, Verheijen JH, Scheeren HW. de Groot FM, et al. Among authors: scheeren hw. J Med Chem. 1999 Dec 16;42(25):5277-83. doi: 10.1021/jm9910472. J Med Chem. 1999. PMID: 10602713

7

"Cascade-release dendrimers" liberate all end groups upon a single triggering event in the dendritic core.

de Groot FM, Albrecht C, Koekkoek R, Beusker PH, Scheeren HW. de Groot FM, et al. Among authors: scheeren hw. Angew Chem Int Ed Engl. 2003 Sep 29;42(37):4490-4. doi: 10.1002/anie.200351942. Angew Chem Int Ed Engl. 2003. PMID: 14520746 No abstract available.

8

Elongated multiple electronic cascade and cyclization spacer systems in activatible anticancer prodrugs for enhanced drug release.

de Groot FM, Loos WJ, Koekkoek R, van Berkom LW, Busscher GF, Seelen AE, Albrecht C, de Bruijn P, Scheeren HW. de Groot FM, et al. Among authors: scheeren hw. J Org Chem. 2001 Dec 28;66(26):8815-30. doi: 10.1021/jo0158884. J Org Chem. 2001. PMID: 11749612

9

Synthesis of novel paclitaxel prodrugs designed for bioreductive activation in hypoxic tumour tissue.

Damen EW, Nevalainen TJ, van den Bergh TJ, de Groot FM, Scheeren HW. Damen EW, et al. Among authors: scheeren hw. Bioorg Med Chem. 2002 Jan;10(1):71-7. doi: 10.1016/s0968-0896(01)00235-8. Bioorg Med Chem. 2002. PMID: 11738608

10

Rearrangement of O-cinnamoyltaxicin I to a novel C-13 spiro-taxane.

van Rozendaal EL, Veldhuis H, van Veldhuizen B, van Beek TA, de Groot A, Beusker PH, Scheeren HW. van Rozendaal EL, et al. Among authors: scheeren hw. J Nat Prod. 2000 Feb;63(2):179-81. doi: 10.1021/np990206h. J Nat Prod. 2000. PMID: 10691703

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

33 results

Search Page

Filters